AU2009219107B2 - Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor - Google Patents

Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor Download PDF

Info

Publication number
AU2009219107B2
AU2009219107B2 AU2009219107A AU2009219107A AU2009219107B2 AU 2009219107 B2 AU2009219107 B2 AU 2009219107B2 AU 2009219107 A AU2009219107 A AU 2009219107A AU 2009219107 A AU2009219107 A AU 2009219107A AU 2009219107 B2 AU2009219107 B2 AU 2009219107B2
Authority
AU
Australia
Prior art keywords
methyl
oxo
diazepan
naphthamide
diphenylethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009219107A
Other languages
English (en)
Other versions
AU2009219107A1 (en
Inventor
Mark Arnold Thomas Blaskovich
Peter Joseph Cassidy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marp Therapeutics Pty Ltd
Original Assignee
Marp Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/391,748 external-priority patent/US8377925B2/en
Application filed by Marp Therapeutics Pty Ltd filed Critical Marp Therapeutics Pty Ltd
Publication of AU2009219107A1 publication Critical patent/AU2009219107A1/en
Application granted granted Critical
Publication of AU2009219107B2 publication Critical patent/AU2009219107B2/en
Assigned to Marp Therapeutics Pty Ltd reassignment Marp Therapeutics Pty Ltd Request for Assignment Assignors: MIMETICA PTY LTD
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009219107A 2008-02-29 2009-02-27 Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor Ceased AU2009219107B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3291208P 2008-02-29 2008-02-29
US61/032,912 2008-02-29
US12/391,748 US8377925B2 (en) 2008-02-29 2009-02-24 Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor
US12/391,748 2009-02-24
PCT/AU2009/000231 WO2009105824A1 (en) 2008-02-29 2009-02-27 Methods of modulating the activity of the mc5 receptor and treatment of conditions related to this receptor

Publications (2)

Publication Number Publication Date
AU2009219107A1 AU2009219107A1 (en) 2009-09-03
AU2009219107B2 true AU2009219107B2 (en) 2013-11-21

Family

ID=41015441

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009219107A Ceased AU2009219107B2 (en) 2008-02-29 2009-02-27 Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor

Country Status (12)

Country Link
EP (1) EP2257297B1 (enExample)
JP (1) JP5503558B2 (enExample)
KR (1) KR101620115B1 (enExample)
CN (1) CN102006873B (enExample)
AU (1) AU2009219107B2 (enExample)
BR (1) BRPI0907906A2 (enExample)
CA (1) CA2716316C (enExample)
IL (1) IL207833B (enExample)
MX (1) MX2010009488A (enExample)
NZ (1) NZ587361A (enExample)
RU (1) RU2555343C9 (enExample)
WO (1) WO2009105824A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008291B2 (en) * 2008-02-29 2011-08-30 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
EP2257533B1 (en) * 2008-02-29 2013-09-18 Mimetica Pty Limited 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists
EP3288534B1 (en) 2015-04-28 2020-09-23 Symrise AG Compositions comprising valerian extracts
GB201808149D0 (en) 2018-05-18 2018-07-11 Univ Court Univ Of Glasgow Protected amino acids
CN115381955B (zh) * 2021-05-24 2024-05-17 中国科学技术大学 黑皮质素受体mc5r的用途
CN114478210A (zh) * 2022-02-26 2022-05-13 江苏壹药新材料有限公司 一种7-氯萘-2-甲醛的合成方法
CN115232015B (zh) * 2022-07-06 2024-01-02 暨明医药科技（苏州）有限公司 一种氯喹手性侧链的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048913A1 (en) * 1998-03-24 1999-09-30 The University Of Queensland Peptide turn mimetics
WO2008017852A1 (en) * 2006-08-11 2008-02-14 Palatin Technologies, Inc. Diamine-containing, tetra- substituted piperazine compounds as melanocortin receptor modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
CN1816337A (zh) * 2003-05-01 2006-08-09 帕拉坦技术公司 黑素皮质素受体特异性化合物
US8008291B2 (en) * 2008-02-29 2011-08-30 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
EP2257533B1 (en) * 2008-02-29 2013-09-18 Mimetica Pty Limited 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048913A1 (en) * 1998-03-24 1999-09-30 The University Of Queensland Peptide turn mimetics
WO2008017852A1 (en) * 2006-08-11 2008-02-14 Palatin Technologies, Inc. Diamine-containing, tetra- substituted piperazine compounds as melanocortin receptor modulators

Also Published As

Publication number Publication date
IL207833A0 (en) 2010-12-30
EP2257297B1 (en) 2017-10-18
NZ587361A (en) 2012-07-27
CA2716316A1 (en) 2009-09-03
IL207833B (en) 2018-02-28
BRPI0907906A2 (pt) 2020-08-18
MX2010009488A (es) 2011-03-02
KR20100134614A (ko) 2010-12-23
JP2011513245A (ja) 2011-04-28
WO2009105824A1 (en) 2009-09-03
EP2257297A1 (en) 2010-12-08
CN102006873B (zh) 2013-09-18
CN102006873A (zh) 2011-04-06
CA2716316C (en) 2017-05-30
RU2555343C9 (ru) 2015-11-27
EP2257297A4 (en) 2012-02-22
RU2010137030A (ru) 2012-04-10
RU2555343C2 (ru) 2015-07-10
KR101620115B1 (ko) 2016-05-12
JP5503558B2 (ja) 2014-05-28
AU2009219107A1 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
AU2009219107B2 (en) Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor
AU2009219106B2 (en) 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
AU2009219108B2 (en) 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists
US9340517B2 (en) Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor
US8343958B2 (en) 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists
HK1149187B (en) Compounds for use in the treatment of acne, seborrhoea and sebhorroeic dermatitis, or for reducing sebum secretion
HK1149187A (en) Compounds for use in the treatment of acne, seborrhoea and sebhorroeic dermatitis, or for reducing sebum secretion
HK1148730B (en) 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
HK1149255B (en) 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: MARP THERAPEUTICS PTY LTD

Free format text: FORMER OWNER(S): MIMETICA PTY LTD

MK14 Patent ceased section 143(a) (annual fees not paid) or expired